CoChat

Rapamycin reduces neuronal mutant huntingtin aggregation and ameliorates locomotor performance in Drosophila

Open access
Roth, Jonathan R., Moraes, Ruan Carlos Macedo de, Xu, Brittney P., Crawley, Savannah R., Khan, Malghalara A., Melkani, Girish C. · 2023 · Frontiers in Aging Neuroscience

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Huntington’s disease (HD) is a neurodegenerative disease characterized by movement and cognitive dysfunction. HD is caused by a CAG expansion in exon 1 of the HTT gene that leads to a polyglutamine (PQ) repeat in the huntingtin protein, which aggregates in the brain and periphery. Previously, we used Drosophila models to determine that Htt-PQ aggregation in the heart causes shortened lifespan and cardiac dysfunction that is ameliorated by promoting chaperonin function or reducing oxidative stress. Here, we further study the role of neuronal mutant huntingtin and how it affects peripheral function. We overexpressed normal (Htt-PQ25) or expanded mutant (Htt-PQ72) exon 1 of huntingtin in Drosophila neurons and found that mutant huntingtin caused age-dependent Htt-PQ aggregation in the brain and could cause a loss of synapsin. To determine if this neuronal dysfunction led to peripheral dysfunction, we performed a negative geotaxis assay to measure locomotor performance and found that neuronal mutant huntingtin caused an age-dependent decrease in locomotor performance. Next, we found that rapamycin reduced Htt-PQ aggregation in the brain. These results demonstrate the role of neuronal Htt-PQ in dysfunction in models of HD, suggest that brain-periphery crosstalk could be important to the pathogenesis of HD, and show that rapamycin reduces mutant huntingtin aggregation in the brain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2023.1223911

Cites

Statistics

Figures

Figure 1 Neuronal Htt-PQ72 aggregates in the brain. (A) Quantification of aggregates in the brain show that PQ-GFP aggregates only in the brains of Elav(II) > Htt-PQ72 flies with age starting at 2 weeks of age (P14), but not in driver control, GFP, or Htt-PQ25 flies (ANOVA for all, P0: p = 1.0 because no variability, N = 8–9 flies per group; P7: F(3,19) = 0.74, p = 0.54, N = 4–7 flies per group; P14: F(3,26) = 4.3, p = 0.01, N = 7–8 flies per group; P28: F(3,42) = 16.6, p < 0.0001, N = 8–13 flies per group). (B) Representative images of flies at eclosion (P0). Scale bar = 100 μm. (C) Representative images of heads at 4 weeks of age (P28) showing aggregation. Yellow boxes show inset displayed below of brains of Elav(II) > GFP flies (i) without aggregates and Elav(II) > Htt-PQ72 flies (ii) with aggregates. Scale bar = 100 μm. (D) Quantification of aggregates in the brain show that PQ-GFP aggregates only in the brains of Elav(X) > Htt-PQ72 flies with age starting by 1 week of age (ANOVA for all, P0: p = 1.0 because no variability, N = 7–9 flies per group; P7: F(3,29) = 35.5, p < 0.0001, N = 8–9 flies per group; P14: F(3,25) = 107.5, p < 0.0001, N = 6–8 flies per group; P21: F(3,40) = 37.7, p < 0.0001, N = 6–14 flies per group). Note the change in y-axis between P7 and P14. (E) Representative images of heads at eclosion (P0). Scale bar = 100 μm. (F) Representative images of heads at 3 weeks of age (P21) showing aggregation. Yellow boxes show inset displayed below of brains of Elav(X) > GFP flies (i) without aggregates and Elav(X) > Htt-PQ72 flies (ii) with aggregates. Note the higher levels of aggregation when driven by Elav(X) compared to Elav(II). All: Data displayed as mean ± SEM. Dunnett’s post hoc. *p < 0.05 and ****p < 0.0001 compared to GFP. Red arrows point to PQ-GFP aggregates in the insets.
Figure 1 Neuronal Htt-PQ72 aggregates in the brain. (A) Quantification of aggregates in the brain show that PQ-GFP aggregates only in the brains of Elav(II) > Htt-PQ72 flies with age starting at 2 weeks of age (P14), but not in driver control, GFP, or Htt-PQ25 flies (ANOVA for all, P0: p = 1.0 because no variability, N = 8–9 flies per group; P7: F(3,19) = 0.74, p = 0.54, N = 4–7 flies per group; P14: F(3,26) = 4.3, p = 0.01, N = 7–8 flies per group; P28: F(3,42) = 16.6, p < 0.0001, N = 8–13 flies per group). (B) Representative images of flies at eclosion (P0). Scale bar = 100 μm. (C) Representative images of heads at 4 weeks of age (P28) showing aggregation. Yellow boxes show inset displayed below of brains of Elav(II) > GFP flies (i) without aggregates and Elav(II) > Htt-PQ72 flies (ii) with aggregates. Scale bar = 100 μm. (D) Quantification of aggregates in the brain show that PQ-GFP aggregates only in the brains of Elav(X) > Htt-PQ72 flies with age starting by 1 week of age (ANOVA for all, P0: p = 1.0 because no variability, N = 7–9 flies per group; P7: F(3,29) = 35.5, p < 0.0001, N = 8–9 flies per group; P14: F(3,25) = 107.5, p < 0.0001, N = 6–8 flies per group; P21: F(3,40) = 37.7, p < 0.0001, N = 6–14 flies per group). Note the change in y-axis between P7 and P14. (E) Representative images of heads at eclosion (P0). Scale bar = 100 μm. (F) Representative images of heads at 3 weeks of age (P21) showing aggregation. Yellow boxes show inset displayed below of brains of Elav(X) > GFP flies (i) without aggregates and Elav(X) > Htt-PQ72 flies (ii) with aggregates. Note the higher levels of aggregation when driven by Elav(X) compared to Elav(II). All: Data displayed as mean ± SEM. Dunnett’s post hoc. *p < 0.05 and ****p < 0.0001 compared to GFP. Red arrows point to PQ-GFP aggregates in the insets.CC BY · PubMed Central
Figure 2 Neuronal Htt-PQ72 can induce synapsin loss in the brain. (A) Quantification of synapsin staining shows a decrease of synapsin in Elav(X) > Htt-PQ72 flies at P21 (ANOVA F(3,39) = 13.6, p < 0.0001, Dunnett’s post hoc ****p < 0.0001 compared to GFP, N = 6–14 flies per group). (B) Quantification of synapsin staining shows no differences in synapsin levels in the brains of flies driven by Elav(II) at P28 (ANOVA F(3,49) = 1.1, p = 0.37, N = 12–16 flies per group). (C) Representative immunofluorescent images stained for presynaptic marker synapsin in the brain of P21 flies driven by Elav(X). Scale bar = 100 μm. (D) Representative images of P28 Elav(II) fly heads stained for synapsin. (E) Quantification of synapsin staining shows no difference between any groups driven by Elav(X) at P7, when aggregates start to form (ANOVA F(3,29) = 1.0, p = 0.39, N = 8–9 flies per group). (F) Representative images of P7 Elav(X) fly heads stained for synapsin. All: Data displayed as mean ± SEM.
Figure 2 Neuronal Htt-PQ72 can induce synapsin loss in the brain. (A) Quantification of synapsin staining shows a decrease of synapsin in Elav(X) > Htt-PQ72 flies at P21 (ANOVA F(3,39) = 13.6, p < 0.0001, Dunnett’s post hoc ****p < 0.0001 compared to GFP, N = 6–14 flies per group). (B) Quantification of synapsin staining shows no differences in synapsin levels in the brains of flies driven by Elav(II) at P28 (ANOVA F(3,49) = 1.1, p = 0.37, N = 12–16 flies per group). (C) Representative immunofluorescent images stained for presynaptic marker synapsin in the brain of P21 flies driven by Elav(X). Scale bar = 100 μm. (D) Representative images of P28 Elav(II) fly heads stained for synapsin. (E) Quantification of synapsin staining shows no difference between any groups driven by Elav(X) at P7, when aggregates start to form (ANOVA F(3,29) = 1.0, p = 0.39, N = 8–9 flies per group). (F) Representative images of P7 Elav(X) fly heads stained for synapsin. All: Data displayed as mean ± SEM.CC BY · PubMed Central
Figure 3 Neuronal Htt-PQ72 decreases climbing muscle performance with age. (A) Negative geotaxis assay demonstrates progressive loss of climbing muscle performance in Elav(II) > Htt-PQ72 flies beginning at P21 (ANOVA for all, P7: F(3,56) = 1.2, p = 0.31, n = 12–19 cohorts per group; P14: F(3,27) = 2.9, p = 0.06, n = 6–9 cohorts per group; P21: F(3,50) = 3.2, p = 0.03, n = 11–15 cohorts per group; P28: F(3,46) = 5.6, p = 0.002, n = 9–15 cohorts per group. All: Dunnett’s post hoc *p < 0.05 and **p < 0.01 compared to GFP). (B) Flight index assay demonstrates no significant difference in flight muscle performance in Elav(II)-driven flies at P28 (ANOVA F(2,7) = 2.2, p = 0.19, n = 3–4 cohorts with N = 14–19 flies per group). (C) Flight index assay demonstrates no significant difference in flight muscle performance in Elav(X)-driven flies at P21 (ANOVA F(2,10) = 1.5, p = 0.29, n = 3–5 cohorts with N = 11–35 flies per group). All: Data displayed as mean ± SEM.
Figure 3 Neuronal Htt-PQ72 decreases climbing muscle performance with age. (A) Negative geotaxis assay demonstrates progressive loss of climbing muscle performance in Elav(II) > Htt-PQ72 flies beginning at P21 (ANOVA for all, P7: F(3,56) = 1.2, p = 0.31, n = 12–19 cohorts per group; P14: F(3,27) = 2.9, p = 0.06, n = 6–9 cohorts per group; P21: F(3,50) = 3.2, p = 0.03, n = 11–15 cohorts per group; P28: F(3,46) = 5.6, p = 0.002, n = 9–15 cohorts per group. All: Dunnett’s post hoc *p < 0.05 and **p < 0.01 compared to GFP). (B) Flight index assay demonstrates no significant difference in flight muscle performance in Elav(II)-driven flies at P28 (ANOVA F(2,7) = 2.2, p = 0.19, n = 3–4 cohorts with N = 14–19 flies per group). (C) Flight index assay demonstrates no significant difference in flight muscle performance in Elav(X)-driven flies at P21 (ANOVA F(2,10) = 1.5, p = 0.29, n = 3–5 cohorts with N = 11–35 flies per group). All: Data displayed as mean ± SEM.CC BY · PubMed Central
Figure 4 Rapamycin reduces Htt-PQ72 aggregation in the brain and ameliorates flight muscle performance. (A) qPCR workflow. Fly heads were isolated for RNA extraction and qPCR was used to compare transcript levels between groups. This image was created in Biorender. (B) Rapamycin increases Atg1 expression (F(1,14) = 7.218, p = 0.0173), Hid expression (F(1,14) = 13.25, p = 0.0027), and pten expression (2-way ANOVA main effect of rapamycin F(1, 14) = 39.7, p < 0.0001); and decreases ilp5 expression (2-way ANOVA main effect of rapamycin F(1, 14) = 10.0, p = 0.007). N = 2–3 cohorts with n = about 10 flies per group per cohort of fly heads. (C) Quantification of PQ-GFP aggregates in Elav(X)-driven flies treated with 200 μM rapamycin or vehicle control for 3 weeks. Rapamycin decreases aggregation in Elav(X) > Htt-PQ72 fly brains (2-way ANOVA interaction F(1,14) = 15.26, p = 0.002, Dunnett’s post hoc ***p < 0.001 compared to vehicle control, N = 2–7 flies per group). (D) Representative fluorescent images of P28 Elav(X)-driven GFP and Htt-PQ72 flies with vehicle control or Rapamycin for 3 weeks. Scale bar = 100 μm. (E) Quantification of synapsin staining shows a decrease of synapsin in Elav(X) > Htt-PQ72 flies at with no effect of rapamycin (2-way ANOVA main effect of genotype F(1,14) = 6.4, p = 0.02, N = 2–7 flies per group). (F) Quantification of PQ-GFP aggregates in Elav(II)-driven flies treated with 200 μM rapamycin or vehicle control for 3 weeks. Rapamycin decreases aggregation in Elav(II) > Htt-PQ72 fly brains (2-way ANOVA interaction F(1,30) = 6.9, p = 0.014, Dunnett’s post hoc ***p < 0.001 compared to vehicle control, N = 6–10 flies per group). (G) Representative fluorescent images of P28 Elav(II) > Htt-PQ72 flies treated with vehicle control or rapamycin for 3 weeks. (H) Rapamycin modifies the loss of climbing performance in Elav(II) > Htt-PQ72 flies at P28 (2-way ANOVA interaction F(1,20) = 5.2, p = 0.03, n = 5–7 cohorts with N = 34–73 flies per group).
Figure 4 Rapamycin reduces Htt-PQ72 aggregation in the brain and ameliorates flight muscle performance. (A) qPCR workflow. Fly heads were isolated for RNA extraction and qPCR was used to compare transcript levels between groups. This image was created in Biorender. (B) Rapamycin increases Atg1 expression (F(1,14) = 7.218, p = 0.0173), Hid expression (F(1,14) = 13.25, p = 0.0027), and pten expression (2-way ANOVA main effect of rapamycin F(1, 14) = 39.7, p < 0.0001); and decreases ilp5 expression (2-way ANOVA main effect of rapamycin F(1, 14) = 10.0, p = 0.007). N = 2–3 cohorts with n = about 10 flies per group per cohort of fly heads. (C) Quantification of PQ-GFP aggregates in Elav(X)-driven flies treated with 200 μM rapamycin or vehicle control for 3 weeks. Rapamycin decreases aggregation in Elav(X) > Htt-PQ72 fly brains (2-way ANOVA interaction F(1,14) = 15.26, p = 0.002, Dunnett’s post hoc ***p < 0.001 compared to vehicle control, N = 2–7 flies per group). (D) Representative fluorescent images of P28 Elav(X)-driven GFP and Htt-PQ72 flies with vehicle control or Rapamycin for 3 weeks. Scale bar = 100 μm. (E) Quantification of synapsin staining shows a decrease of synapsin in Elav(X) > Htt-PQ72 flies at with no effect of rapamycin (2-way ANOVA main effect of genotype F(1,14) = 6.4, p = 0.02, N = 2–7 flies per group). (F) Quantification of PQ-GFP aggregates in Elav(II)-driven flies treated with 200 μM rapamycin or vehicle control for 3 weeks. Rapamycin decreases aggregation in Elav(II) > Htt-PQ72 fly brains (2-way ANOVA interaction F(1,30) = 6.9, p = 0.014, Dunnett’s post hoc ***p < 0.001 compared to vehicle control, N = 6–10 flies per group). (G) Representative fluorescent images of P28 Elav(II) > Htt-PQ72 flies treated with vehicle control or rapamycin for 3 weeks. (H) Rapamycin modifies the loss of climbing performance in Elav(II) > Htt-PQ72 flies at P28 (2-way ANOVA interaction F(1,20) = 5.2, p = 0.03, n = 5–7 cohorts with N = 34–73 flies per group).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 73 · Cited by 16

Research works printed but not linked: 1

  1. Assaying locomotor, learning, and memory deficits in Drosophila models of neurodegeneration2504 AliY. O. EscalaW. RuanK. ZhaiR. G. 10.3791/2504J. Vis. Exp.112011 · doi:10.3791/2504j

Metadata

Authors
Roth, J. R., Moraes, R. C. M. D., Xu, B. P., Crawley, S. R., Khan, M. A., & Melkani, G. C.
Affiliations
University of Alabama at Birmingham (US)
Corresponding author
Melkani, Girish C.
Venue
Frontiers in Aging Neuroscience
Published
2023-09-26
Volume
15
Pages
1223911-1223911
ISSN
1663-4365 (ISSN-L)
OpenAlex
W4387106053
Cited by
16
References
73
Citations by year
2026: 4 · 2025: 6 · 2024: 5 · 2023: 1
FWCI
1.93
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Aging Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (AG065992, AG068550)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
Huntington's disease, mutant huntingtin, polyglutamine aggregation, rapamycin, neuronal dysfunction, locomotor performance, synapsin, age-related neurodegeneration, Drosophila model, mTOR inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapamycin reduces neuronal mutant huntingtin aggregation and ameliorates locomotor performance in Drosophila. https://app.cochat.ai/papers/10.3389/fnagi.2023.1223911
The paper
Roth, J. R., Moraes, R. C. M. D., Xu, B. P., Crawley, S. R., Khan, M. A., & Melkani, G. C. (2023). Rapamycin reduces neuronal mutant huntingtin aggregation and ameliorates locomotor performance in Drosophila. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2023.1223911

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.